Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 53Neoplasms 23Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Lung Neoplasms 12Head and Neck Neoplasms 11Neoplasm Metastasis 8Carcinoma, Squamous Cell 7Pancreatic Neoplasms 6Colorectal Neoplasms 6Stomach Neoplasms 5Esophageal Squamous Cell Carcinoma 5Prostatic Neoplasms 4Multiple Myeloma 4Esophageal Neoplasms 4Lymphoma 3Hematologic Neoplasms 3Glioblastoma 3Brain Neoplasms 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Non-small-cell Lung Cancer With Somatic EGFR Mutations 2Melanoma 2Glioma 2Colonic Neoplasms 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urethral Neoplasms 1

Interventions

Fluorouracil 218Leucovorin 201Oxaliplatin 191Irinotecan 148Bevacizumab 107Capecitabine 93Cetuximab 89Folfox protocol 54Chemotherapy, Adjuvant 34Panitumumab 30pembrolizumab 23Nivolumab 22Colonoscopy 22Gemcitabine 20Magnetic Resonance Spectroscopy 19Floxuridine 19IFL protocol 18Celecoxib 18Radiotherapy 17Neoadjuvant Therapy 17Early Intervention, Educational 17Drug Therapy 17Laparoscopy 14Cyclophosphamide 14Counseling 14trifluridine tipiracil drug combination 13regorafenib 13XELOX 13Exercise 13Erlotinib Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Colonic Neoplasms × Afatinib × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03785249 2025-09-30

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Mirati Therapeutics Inc.

Phase 1/2 Active not recruiting
731 enrolled 1 FDA
Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡